Recruiting Fibromyalgia Studies in Aurora
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptim...
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia ...
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be...
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants wit...
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combina...
Bionic Pancreas in CFRD
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using...
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (...
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that char...
About Fibromyalgia Clinical Trials in Aurora
Fibromyalgia is a condition characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive difficulties. It affects about 2-4% of the population, predominantly women. Treatment includes medications, exercise, stress management, and cognitive behavioral therapy.
There are currently 8 fibromyalgia clinical trials recruiting participants in Aurora, COLORADO. These studies are seeking a combined 2,160 participants. Research is being sponsored by Kartos Therapeutics, Inc., Swedish Orphan Biovitrum, Karyopharm Therapeutics Inc and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Fibromyalgia Clinical Trials in Aurora — FAQ
Are there fibromyalgia clinical trials in Aurora?
Yes, there are 8 fibromyalgia clinical trials currently recruiting in Aurora, COLORADO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Aurora?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.
Are clinical trials in Aurora free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.
What fibromyalgia treatments are being tested?
The 8 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for fibromyalgia.
Data updated March 2, 2026 from ClinicalTrials.gov